prochlorperazine
Ligand Summary
A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)
UNII: YHP6YLT61T
PubChem: 4917
Guide to Pharmacology: 7279
ChEMBL: CHEMBL728
DrugCentral: 2274
LyCHI: J4UYVBWGRUP1
Target Activities
DRD2
D(2) dopamine receptor
4 Activities
Items per page:
1 – 4 of 4
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 8.44 | |||||
Ki | 8.44 | None, None:None:None | ||||
IC50 | 7.96 | None, None:None:None | ||||
Ki | 8.76 | ANTAGONIST | ||||
DRD3
D(3) dopamine receptor
4 Activities
Items per page:
1 – 4 of 4
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 8.35 | |||||
Ki | 8.35 | None, None:None:None | ||||
IC50 | 7.89 | None, None:None:None | ||||
Ki | 8.61 | ANTAGONIST | ||||
CYP2D6
Cytochrome P450 2D6
3 Activities
Items per page:
1 – 3 of 3
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
IC50 | 6.52 | None, None:None:None | ||||
AC50 | 6.4 | None, None:None:None | ||||
AC50 | 6.1 | None, None:None:None | ||||
DRD1
D(1A) dopamine receptor
2 Activities
Items per page:
1 – 2 of 2
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 7.11 | |||||
Ki | 7.11 | None, None:None:None | ||||
HRH1
Histamine H1 receptor
2 Activities
Items per page:
1 – 2 of 2
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 8.55 | None, None:None:None | ||||
IC50 | 7.62 | None, None:None:None | ||||
SIGMAR1
Sigma non-opioid intracellular receptor 1
2 Activities
Items per page:
1 – 2 of 2
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 7.64 | None, None:None:None | ||||
IC50 | 7.27 | None, None:None:None | ||||
ADRA1D
Alpha-1D adrenergic receptor
2 Activities
Items per page:
1 – 2 of 2
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 7.8 | None, None:None:None | ||||
IC50 | 7.47 | None, None:None:None | ||||
ADRA2B
Alpha-2B adrenergic receptor
2 Activities
Items per page:
1 – 2 of 2
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 8.32 | None, None:None:None | ||||
IC50 | 8 | None, None:None:None | ||||
KCNH2
Potassium voltage-gated channel subfamily H member 2
2 Activities
Items per page:
1 – 2 of 2
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 5.82 | None, None:None:None | ||||
IC50 | 5.73 | None, None:None:None | ||||
HTR2A
5-hydroxytryptamine receptor 2A
2 Activities
Items per page:
1 – 2 of 2
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 8.7 | None, None:None:None | ||||
IC50 | 8.15 | None, None:None:None | ||||
HTR2C
5-hydroxytryptamine receptor 2C
2 Activities
Items per page:
1 – 2 of 2
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 7.39 | None, None:None:None | ||||
IC50 | 7.11 | None, None:None:None | ||||
SLC6A2
Sodium-dependent noradrenaline transporter
2 Activities
Items per page:
1 – 2 of 2
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
IC50 | 6.4 | None, None:None:None | ||||
Ki | 6.4 | None, None:None:None | ||||
ADRA2C
Alpha-2C adrenergic receptor
2 Activities
Items per page:
1 – 2 of 2
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 7.92 | None, None:None:None | ||||
IC50 | 7.09 | None, None:None:None | ||||
DRD4
D(4) dopamine receptor
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 6.09 | |||||
HTR2B
5-hydroxytryptamine receptor 2B
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 7.19 | None, None:None:None | ||||
ADRA2A
Alpha-2A adrenergic receptor
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 7.2 | None, None:None:None | ||||
SLC6A4
Sodium-dependent serotonin transporter
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
Ki | 6.21 | None, None:None:None | ||||
CYP1A2
Cytochrome P450 1A2
1 Activities
Items per page:
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
AC50 | 6 | None, None:None:None | ||||